Find a Tender
complete
Official procurement procedure
(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.
Business and management consultancy and related services
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Newcastle University: "(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Newcastle University | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: Newcastle University
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Newcastle University. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
2.4Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 104 active published awards; 98 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNewcastle University | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSDynamic market | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published30 Sept 2022, 09:41 BST | Last source update30 Sept 2022, 09:41 BST | Recurring procurementNot published |
ClassificationBusiness and management consultancy and related services | ||
Delivery area | ||
OCIDocds-h6vhtk-03719a | ||
What is being bought
Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively.
The initial brief of the executive will be to:
Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck;
Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board
Phase (3) January 2023-March 2023 – a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University;
b. Work with the Unit TT team to obtain founder academics’ and University approval for appointment as CEO.
c. Provide to the University of Bath all matters necessary for Research England reporting requirements.
Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding
Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.
What changed
From the official release history
- Status changed to complete
30 Sept 2022, 09:41 BST - Official notice release published
30 Sept 2022, 09:41 BST - Buyer information updated
30 Sept 2022, 09:41 BST
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcancelledPublished valueNot publishedCancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively. The initial brief of the executive will be to: Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck; Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board Phase (3) January 2023-March 2023 – a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University; b. Work with the Unit TT team to obtain founder academics’ and University approval for appointment as CEO. c. Provide to the University of Bath all matters necessary for Research England reporting requirements. Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
30 Sept 2022, 09:41 BST - Award active
Not published · Not published - Contract active
Signed 21 Sept 2022, 00:00 BST · £30,000
Commercial outcome and competition
Awards Cambridge Drug Discovery Not published · Not published · active |
Contracts Contract £30,000 · signed 21 Sept 2022, 00:00 BST · active |
Bid statistics bids: 3 (lot 1) electronicBids: 3 (lot 1) foreignBidsFromEU: 0 (lot 1) foreignBidsFromNonEU: 3 (lot 1) smeBids: 3 (lot 1) |
Buyer and organisations in this procedure
Newcastle University
Contracting authority GB-FTS-168Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleNot published |